When to Stop or Reduce Eliquis (Apixaban)
Apixaban should be dose-reduced to 2.5 mg twice daily when patients meet at least TWO of three criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, and must be stopped 24-48 hours before surgery depending on bleeding risk. 1
Dose Reduction Criteria for Atrial Fibrillation
The FDA-approved dose reduction from 5 mg to 2.5 mg twice daily requires at least 2 of the following 3 criteria 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical caveat: Patients with only ONE criterion should remain on the full 5 mg twice daily dose. The ARISTOTLE trial demonstrated that patients with a single dose-reduction criterion maintained consistent safety and efficacy with standard dosing 2. Off-label dose reduction in patients not meeting criteria has been associated with increased mortality without clear benefit 3.
Renal Dosing Adjustments
For patients with renal impairment 4:
- CrCl >50 mL/min: Standard 5 mg twice daily (or 2.5 mg if meeting 2+ criteria above)
- CrCl 15-50 mL/min: Continue 5 mg twice daily unless meeting 2+ dose-reduction criteria
- CrCl 15-30 mL/min: 5 mg twice daily is approved (2.5 mg if meeting criteria)
- CrCl <15 mL/min or dialysis: 5 mg twice daily remains approved, though apixaban has 27% renal clearance making it preferable in severe renal dysfunction 5
The European guidance suggests apixaban may be preferable in severe CKD due to its lower renal clearance compared to other DOACs 5.
Perioperative Management: When to Stop
Timing of discontinuation before surgery 4, 1:
Low Bleeding Risk Procedures
- Stop 1 day (24 hours) before procedure for CrCl >25 mL/min
- This means no dose on the day before surgery and no dose on surgery day
High Bleeding Risk Procedures
- Stop 2 days (48 hours) before procedure for CrCl >25 mL/min
- For CrCl <25 mL/min: Consider holding an additional 1-3 days 4
Important clarification: "1 day" means one full day without medication. For example, if taking apixaban at 8 PM and surgery is at 8 AM, the last dose would be 36 hours before surgery 4.
Research confirms that 48-hour cessation results in clinically insignificant anticoagulation levels (≤30 ng/mL in 94% of patients), though median actual cessation time in practice was 76 hours 6.
Bridging anticoagulation is NOT generally required during the 24-48 hour interruption period 1.
When to Resume After Surgery
Restart apixaban as soon as adequate hemostasis is established 1. The initial post-surgical dose should be taken 12-24 hours after the procedure for orthopedic surgeries 1.
Drug Interactions Requiring Dose Reduction
When combined P-gp and strong CYP3A4 inhibitors are used (ketoconazole, itraconazole, ritonavir) 1:
- Patients on 5 mg or 10 mg twice daily: Reduce dose by 50%
- Patients already on 2.5 mg twice daily: Avoid coadministration
Special Populations
Cancer-Associated VTE
After completing 6 months of full-dose therapy (5 mg twice daily), dose reduction to 2.5 mg twice daily for extended prophylaxis is superior - it reduces bleeding by 25% (HR 0.75) without increasing recurrent VTE 7. This represents a major shift from traditional full-dose extended therapy.
Chronic Kidney Disease
In patients with advanced CKD or on dialysis, apixaban's lower renal clearance (27%) makes it a preferred DOAC, though plasma levels may be supra-therapeutic even at reduced doses 5. The 2.5 mg twice daily dose in dialysis patients achieves levels similar to standard dosing in patients with normal renal function 5.
Critical Warnings About Inappropriate Dosing
Do not empirically reduce doses outside FDA criteria. While 17% of patients receive off-label reduced dosing in practice 3, this approach shows no benefit and is associated with 10.9% vs 1.4% mortality compared to appropriate standard dosing 3. Conversely, inappropriately reduced dosing significantly increases thromboembolic risk 8.
The dose-reduction criteria exist because pharmacokinetic studies showed increased apixaban exposure in these specific populations, but clinical outcomes data confirm that patients with only one criterion do NOT benefit from dose reduction 9, 2.